Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

Completed

Conditions studied: Acute Kidney Injury

In brief

To compare, by insulin use at the index date, the incidence of hospitalization for acute kidney injury (AKI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy

Key facts

Study ID

NCT02695082

Run by

AstraZeneca

People needed

539310

Starts

2017-01-01

Expected to finish

2020-11-30

Last updated by the study team

2021-12-07

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• receive newly prescribed dapagliflozin (with or without other ADs) or receive a newly prescribed AD (with or without other ADs) in a class other than SGLT2 inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy;
• do not have any diagnostic code indicating type1 diabetes;
• are aged 18 years or older at the index date for CPRD patients, 18-64 years for HIRDSM patients, or 65 years or older for Medicarepatients; and
• have been enrolled in the data source for at least 180 days before the first prescription or dispensing dapagliflozin or eligible index comparator AD

You may not qualify if…

• previous diagnosis of chronic kidney failure

Where it is running

• Research Site — Wilmington, Delaware, United States
• Research Site — Washington D.C., District of Columbia, United States
• Research Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.